Close

Anti-CD7 (3A1e) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP3240)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD7 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD7. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD7 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of T-cell acute lymphocytic leukemia (T-ALL) .

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD7
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • T-cell acute lymphocytic leukemia (T-ALL)
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 3A1e
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CD7
  • Synonyms
  • CD7 molecule; GP40; TP41; Tp40; LEU-9

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Expanded CD7KO CD7 CAR T cells eradicate T-ALL and T lymphoma cell lines.

CAR Construction : 3A1e-CD28-CD3ζ Latest CAR Construction

Fig.1 Expanded CD7KO CD7 CAR T cells eradicate T-ALL and T lymphoma cell lines.

Absolute counts of live tumor cells were measured by flow cytometry using counting beads at the end of coculture with CD7KO CD7 CAR T cells.

Gomes-Silva, D., Srinivasan, M., Sharma, S., Lee, C. M., Wagner, D. L., Davis, T. H., ... & Mamonkin, M. (2017). CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood, The Journal of the American Society of Hematology, 130(3), 285-296.

Complete CAR data FCM

Fig.2 CD7KO CD7 CAR T cells eradicate AML Cell Lines.

CAR Construction : 3A1e-CD28-CD3ζ Latest CAR Construction

Fig.2 CD7KO CD7 CAR T cells eradicate AML Cell Lines.

Absolute counts of live AML cells were measured by flow cytometry using counting beads at the end of coculture with CD7KO CD7 CAR T cells.

Gomes-Silva, D., Atilla, E., Atilla, P. A., Mo, F., Tashiro, H., Srinivasan, M., ... & Mamonkin, M. (2019). CD7 CAR T cells for the therapy of acute myeloid leukemia. Molecular Therapy, 27(1), 272-280.

Complete CAR data FCM

Fig.3 Determination of cytokines release.

CAR Construction : 3A1e-CD28-CD3ζ Latest CAR Construction

Fig.3 Determination of cytokines release.

Representative dot plots showing intracellular cytokine staining for TNFα and IFNγ in CD7KO CD7 CAR T cells upon coculture with CCRF cells or media alone.

Gomes-Silva, D., Srinivasan, M., Sharma, S., Lee, C. M., Wagner, D. L., Davis, T. H., ... & Mamonkin, M. (2017). CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood, The Journal of the American Society of Hematology, 130(3), 285-296.

Complete CAR data FCM

Fig.4 Determination of IFNγ production.

CAR Construction : 3A1e-CD28-CD3ζ Latest CAR Construction

Fig.4 Determination of IFNγ production.

IFNγ production by CD8+and CD4+CD7 CAR T cells upon 4-hr coculture with indicated AML cell lines by intracellular cytokine staining and flow cytometry.

Gomes-Silva, D., Atilla, E., Atilla, P. A., Mo, F., Tashiro, H., Srinivasan, M., ... & Mamonkin, M. (2019). CD7 CAR T cells for the therapy of acute myeloid leukemia. Molecular Therapy, 27(1), 272-280.

Complete CAR data BI

Fig.5 CD7KO CD7 CAR T cells control the progression of systemic T-ALL in the mouse xenograft model.

CAR Construction : 3A1e-CD28-CD3ζ Latest CAR Construction

Fig.5 CD7KO CD7 CAR T cells control the progression of systemic T-ALL in the mouse xenograft model.

NSG mice were injected intravenously with GFP-FFluc CCRF cells followed by a single intravenous injection of control or CD7KO CD7 CAR T cells 3 days later.

Gomes-Silva, D., Srinivasan, M., Sharma, S., Lee, C. M., Wagner, D. L., Davis, T. H., ... & Mamonkin, M. (2017). CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood, The Journal of the American Society of Hematology, 130(3), 285-296.

Complete CAR data BI

Fig.6 CD7 CAR T cells control the progression of systemic AML in vivo.

CAR Construction : 3A1e-CD28-CD3ζ Latest CAR Construction

Fig.6 CD7 CAR T cells control the progression of systemic AML in vivo.

NSG mice received FFluc-expressing KG-1a cells 24 hr after sublethal irradiation with 116 cGy. Eight days later, mice received a single injection of control or CD7 CAR T cells intravenously and were monitored for tumor progression.

Gomes-Silva, D., Atilla, E., Atilla, P. A., Mo, F., Tashiro, H., Srinivasan, M., ... & Mamonkin, M. (2019). CD7 CAR T cells for the therapy of acute myeloid leukemia. Molecular Therapy, 27(1), 272-280.

Complete CAR data Cyt

Fig.7 In vitro cytotoxicity of base-edited CD3CAR and CD7CAR cells.

CAR Construction : 3A1e-41BB-CD3ζ Latest CAR Construction

Fig.7 In vitro cytotoxicity of base-edited CD3CAR and CD7CAR cells.

51Cr labelled Jurkat T cells modified to express CD3+CD7+, CD3+CD7−, CD3−CD7+ or CD3−CD7− were co-cultured with either CD3CAR , CD7CAR , mixed CD3CAR/CD7CAR or untransduced cells at an increasing ratio of effectors:targets (E:T).

Georgiadis, C., Rasaiyaah, J., Gkazi, S. A., Preece, R., Etuk, A., Christi, A., & Qasim, W. (2021). Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia, 35(12), 3466-3481.

Complete CAR data BI

Fig.8 CD3CAR and CD7CAR T cells exhibit potent anti-leukaemic effects in vivo.

CAR Construction : 3A1e-41BB-CD3ζ Latest CAR Construction

Fig.8 CD3CAR and CD7CAR T cells exhibit potent anti-leukaemic effects in vivo.

CD3CAR or CD7CAR cells edited using either SpCas9 or coBE3 mRNA were infused intravenously on day 4 alongside PBS and untransduced controls and leukaemic progression was monitored by serial bioluminescent imaging on over four weeks.

Georgiadis, C., Rasaiyaah, J., Gkazi, S. A., Preece, R., Etuk, A., Christi, A., & Qasim, W. (2021). Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia, 35(12), 3466-3481.

Complete CAR data FCM

Fig.9 Cell apoptosis analysis.

CAR Construction : 3A1e-OX40-CD28-CD3ζ Latest CAR Construction

Fig.9 Cell apoptosis analysis.

Cell apoptosis results revealed that the proportions of both early and late apoptotic cells in the anti-CD7 CAR-T cell groups were higher than those in the mock group and the anti-CD19 CAR-T cell group. Anti-CD7 CAR-T cells may induce fratricide because of T cell expression of CD7.

Ye, J., Jia, Y., Tuhin, I. J., Tan, J., Monty, M. A., Xu, N., ... & Yu, L. (2022). Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Molecular Therapy-Oncolytics, 24, 719-728.

Complete CAR data Cyt

Fig.10 Anti-CD7 CAR-T cells cultured with an antibody possess strong cytotoxicity against CD7-positive tumor cells.

CAR Construction : 3A1e-OX40-CD28-CD3ζ Latest CAR Construction

Fig.10 Anti-CD7 CAR-T cells cultured with an antibody possess strong cytotoxicity against CD7-positive tumor cells.

The cytotoxicity of nontransduced T cells (mock) and anti-CD7 CAR-T cells cultured with the PUT644 antibody against target Jurkat cells was evaluated.

Ye, J., Jia, Y., Tuhin, I. J., Tan, J., Monty, M. A., Xu, N., ... & Yu, L. (2022). Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Molecular Therapy-Oncolytics, 24, 719-728.

CAR scFv data SPR

Fig.11 The binding affinity measurement of 3Ale scfv and Fab to CD7-Rg.

CAR Construction : Latest CAR Construction

Fig.11 The binding affinity measurement of 3Ale scfv and Fab to CD7-Rg.

Representative sensorgrams depicting the binding of 3Ale sFv (B), 3Ale Fab (D) to CD7-Rg (470 RU) were generated using a BlAcore instrument.

Pauza, M. E., Doumbia, S. O., & Pennell, C. A. (1997). Construction and characterization of human CD7-specific single-chain Fv immunotoxins. The Journal of Immunology, 158(7), 3259-3269.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD7 (3A1e) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP3240). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.